Andrea Carta Mantegia
Partner and former Managing Partner (2019–2023) of BonelliErede, leading the Healthcare & Life Sciences Focus Team; specialist in M&A and corporate law.
1
APPEARANCES
1
PODCASTS
Jul 14, 2026
Nicole RaleighHOST
I was wondering if you could speak to how the factors driving M&A activity in the US are different from those in Europe.
3:44
Let me start from a, a, a general scenario, uh, of the M&A that, uh, could be useful to, uh, as setting the, the proper perspective.
3:55
Um, I, I believe that, uh, uh, we are in a era of growth in the life science, uh, sector, but, uh, it's a different growth from, uh, what you see in other industry.
4:13
Uh, which means that, uh, uh, targets, uh, uh, for M&A are chosen more carefully than they d- than they used before.
4:25
And, and the, the real challenge is choice, not capital, uh, meaning that, uh, uh, there is more competition on a limited pool of opportunities.
4:37
Uh, and you can see that, uh, in, in recent, uh, battles to, uh, to, to, to, uh, acquire certain targets, uh, all around the world.
7 MINS LATER
Nicole RaleighHOST
I was wondering what you could tell us about the growing role of private equity in European pharma and med tech.